Bristol-Myers Squibb (BMY) Stock News
$BMY · NYSE · HEALTHCARE · 5 stories in 30 daysBORSA has published 5 stories on Bristol-Myers Squibb (BMY) in the past 30 days, 3 of them high impact. BORSA’s news read on BMY is bullish at 66/100, unchanged over 24 hours, based on 4 company events over the past 7 days. BMY last closed at $59.12 on Oct 9, down 3.32% over five sessions and down 6.31% over the past month. Bristol-Myers Squibb’s next earnings report is scheduled for Thursday, Oct 29 before the open.
The wire on $BMY
newest first · updated · direct subject stories onlyWells Fargo lowered its price target for Bristol-Myers Squibb from $65.00 to $60.00.
bearish 35 · impact 30Bristol-Myers Squibb announced that its Phase 3 ALOFT-PPF trial evaluating admilparant in progressive pulmonary fibrosis is ongoing, with topline results expected in early 2027. This is the companion trial to the ALOFT-IPF study, which recently met its primary endpoint at the 60 mg dose.
